179 related articles for article (PubMed ID: 35851309)
1. Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity.
Tang T; Huang X; Zhang G; Liang T
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851309
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis.
Tang T; Huang X; Zhang G; Lu M; Hong Z; Wang M; Huang J; Zhi X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288467
[TBL] [Abstract][Full Text] [Related]
3. The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade.
Najafi S; Majidpoor J; Mortezaee K
Biomed Pharmacother; 2023 May; 161():114436. PubMed ID: 36841031
[TBL] [Abstract][Full Text] [Related]
4. ANTICANCER IMMUNOGENIC POTENTIAL OF ONCOLYTIC PEPTIDES: RECENT ADVANCES AND NEW PROSPECTS.
Khranovska N; Skachkova O; Gorbach O; Semchuk I; Shvets Y; Komarov I
Exp Oncol; 2024 May; 46(1):3-12. PubMed ID: 38852058
[TBL] [Abstract][Full Text] [Related]
5. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
Romano G; Marino IR
Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy.
Zamarin D; Ricca JM; Sadekova S; Oseledchyk A; Yu Y; Blumenschein WM; Wong J; Gigoux M; Merghoub T; Wolchok JD
J Clin Invest; 2018 Apr; 128(4):1413-1428. PubMed ID: 29504948
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Chaurasiya S; Yang A; Kang S; Lu J; Kim SI; Park AK; Sivanandam V; Zhang Z; Woo Y; Warner SG; Fong Y
Oncoimmunology; 2020; 9(1):1729300. PubMed ID: 32158622
[TBL] [Abstract][Full Text] [Related]
8. Polymer chimera of stapled oncolytic peptide coupled with anti-PD-L1 peptide boosts immunotherapy of colorectal cancer.
Lu L; Zhang H; Zhou Y; Lin J; Gao W; Yang T; Jin J; Zhang L; Nagle DG; Zhang W; Wu Y; Chen H; Luan X
Theranostics; 2022; 12(7):3456-3473. PubMed ID: 35547769
[No Abstract] [Full Text] [Related]
9. Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors.
Su Y; Li J; Ji W; Wang G; Fang L; Zhang Q; Ang L; Zhao M; Sen Y; Chen L; Zheng J; Su C; Qin L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35609942
[TBL] [Abstract][Full Text] [Related]
10. Improving cancer immunotherapy by rationally combining oncolytic virus with modulators targeting key signaling pathways.
Zhu Z; McGray AJR; Jiang W; Lu B; Kalinski P; Guo ZS
Mol Cancer; 2022 Oct; 21(1):196. PubMed ID: 36221123
[TBL] [Abstract][Full Text] [Related]
11. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.
Marchini A; Daeffler L; Pozdeev VI; Angelova A; Rommelaere J
Front Immunol; 2019; 10():1848. PubMed ID: 31440242
[TBL] [Abstract][Full Text] [Related]
12. Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy.
Zhang B; Cheng P
Mol Cancer; 2020 Nov; 19(1):158. PubMed ID: 33172438
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cell delivery of oncolytic immunotherapy improves CAR-T cell antitumor activity.
McKenna MK; Englisch A; Brenner B; Smith T; Hoyos V; Suzuki M; Brenner MK
Mol Ther; 2021 May; 29(5):1808-1820. PubMed ID: 33571680
[TBL] [Abstract][Full Text] [Related]
14. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses.
Wang G; Kang X; Chen KS; Jehng T; Jones L; Chen J; Huang XF; Chen SY
Nat Commun; 2020 Mar; 11(1):1395. PubMed ID: 32170083
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
Ripp J; Hentzen S; Saeed A
Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition.
Cervera-Carrascon V; Quixabeira DCA; Santos JM; Havunen R; Zafar S; Hemminki O; Heiniö C; Munaro E; Siurala M; Sorsa S; Mirtti T; Järvinen P; Mildh M; Nisen H; Rannikko A; Anttila M; Kanerva A; Hemminki A
Oncoimmunology; 2020 May; 9(1):1761229. PubMed ID: 32923123
[TBL] [Abstract][Full Text] [Related]
17. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
18. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
19. Unleashing the therapeutic potential of oncolytic viruses.
Bommareddy PK; Kaufman HL
J Clin Invest; 2018 Apr; 128(4):1258-1260. PubMed ID: 29504947
[TBL] [Abstract][Full Text] [Related]
20. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]